Quetiapine Fumarate Oral Tablets (Immediate-Release) Suppliers & Bulk Manufacturers
Available Forms: Oral tablets (Immediate-Release)
Available Strengths: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg
Reference Brands: US: Seroquel®, Seroquel XR®; EU: Seroquel®, Seroquel Prolong®, Quetiapine Teva®
Category:
Antipsychotropic Drugs
Quetiapine IR is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, helping manage psychotic and mood disorders. It’s used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder adjunct therapy, providing flexible dosing for acute symptom control and improved mental health outcomes.
Quetiapine Fumarate Oral tablets (Immediate-Release) is available in Oral tablets (Immediate-Release)
and strengths such as 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Quetiapine Fumarate Oral tablets (Immediate-Release) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Quetiapine Fumarate Oral tablets (Immediate-Release) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Quetiapine Fumarate Immediate-Release tablets are FDA-approved in the USA for treating schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder. As an atypical antipsychotic, it carries a Boxed Warning regarding increased risk of suicidal thoughts and elderly dementia-related psychosis. Manufacturers must adhere to GMP standards, accurate labeling, and post-marketing surveillance. In the European Union, it is authorized through national or mutual recognition procedures, with obligations for Risk Management Plans (RMPs), Periodic Safety Update Reports (PSURs), and bioequivalence for generics. Discover dossier-complete Quetiapine IR tablets at Pharmatradz.com for global B2B sourcing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing